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Inconsistent evidence has been reported on the role of female hormonal factors in the development of lung
cancer. This population-based case–control study evaluated the main effect of menstrual/reproductive factors on
the risk of lung cancer, and the effect modification by smoking status. Multivariable unconditional logistic
regression models were applied adjusted for age, income, education, county of residence, body mass index,
smoking status, pack-years of smoking, and family history of lung cancer. Among 680 lung cancer cases and 1,808
controls, later menopause (at N54 vs. b46 years old) was associated with increased risk of lung cancer (SBOR,
semi-Bayes adjusted odds ratio = 1.61, 95% PI, posterior interval = 1.10–2.36). More pregnancies (2 or 3 vs. 0 or
1) was associated with decreased risk (SBOR = 0.71, 95% PI = 0.53, 0.95). Ever being a smoker and having two
or fewer pregnancies in one's lifetime could jointly increase the odds of lung cancer (RERI, relative excess risk due
to interaction = 1.71, 95% CI = 0.03, 3.38). An increased number of ovulatory cycles was associated with
increased risk of lung cancer (SBOR for 13 ovulatory cycles = 1.02, 95% CI = 1.00+, 1.04).
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ung cancer is the most common and deadly cancer with the highest
mber of new cases (2,093,876) and deaths (1,761,007) in 2018
cording to GLOBOCAN estimation [1]. It was also estimated that
.0% of new lung cancer cases and 39.2% of lung cancer deaths
ppened in China in 2018 [2]. According to the CONCORD-3
udy [3]and SEER project [4], the 5-year survival rate of lung cancer
as 19.8% in China and 21.2% in the USA.
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820 Smoking, Hormonal Factors, and Lung Cancer Jin et al. Translational Oncology Vol. 12, No. 6, 2019Tobacco smoking is believed to be the leading cause of lung cancer
], with very high attributable risks (about 90% for men and 60%
r women [6]) and odds ratios (23.6 for current male smokers and
8 for current female smokers respectively [6,7]. Smoking is more
rongly associated with squamous cell carcinoma (SCC) and small
ll carcinoma than with adenocarcinoma.
In smokers, pack-years [7–9] of smoking, cumulative tar exposure
tobacco products [10] and smoking intensity [7] are positively
sociated with the risk of lung cancer. Among non-smokers,
vironmental tobacco smoking (ETS or second hand smoking)
s been shown associated with increased risk of lung cancer for all
ajor histologic types [9].
Men and women differ in terms of lung cancer risk, survival,
stology, and genetics. In the US, the lung cancer incidence rate in
en peaked around the 1980s and decreased since the 1980s. On the
her hand, rates continued to rise among women until 2010 [11]
d started to drop in the past couple of years [12]. Women tend to
ve increased risk of getting lung cancer among non-smokers
3–15] and women have better lung cancer survival than men
obally. According to GLOBOCAN estimation in 2018 [1], 34.6%
new lung cancer cases and 32.7% lung cancer deaths happened in
omen. There is a lower proportion of SCC and a higher proportion of
enocarcinoma in women than in men [14]. In NSCLC (non-small
ll lung cancer) patients, EGFR (Epidermal growth factor receptor)
utations are more frequent in female than inmale (more than 40% vs.
ss than 15%) [16]. Among current smokers, female patients had a 3.9-
ld median level of CYP1A1 (Cytochrome P450 1A1) mutation
mpared tomales [17]. After all measurable lifestyle and unchangeable
ctors are accounted for, the occurrences of lung cancer are still
balanced between men and women [13–15]. These facts suggested
at female sex hormones, especially estrogen, may have played a role in
e initiation and progression of lung tumors [13,14].
Estrogen has long been associated with cancer development
8,19]. The amount of circulating estrogen and exogenous estrogen
termines the effect of ERs (estrogen receptor) on cell proliferation
d carcinogenesis. Menstrual and reproductive factors are commonly
ed as proxies for life-long endogenous estrogen exposure in women,
hile oral contraceptive use (OC) and hormone replacement therapy
RT) represent exogenous sources of estrogen.
The results from epidemiologic studies on hormonal factors and
e risk of lung cancer [20–27] were generally inconsistent [28]. In
der to improve the validity and precision in the investigation of the
sociations between menstrual/reproductive history and the risk of
ng cancer, and to investigate the effect modification by smoking
atus, we conducted the present analysis using data from the Jiangsu
our Cancers (JFC) Study.th
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The JFC Study is a large-scale, population-based case–control study
cancers of the lung, liver, stomach, and esophagus conducted in four
unties in Jiangsu, China. It was carried out in an effort to obtain high-
ality data to investigate the lifestyle, environmental, and genetic
ctors associated with the four major cancers in China [29].
The incident primary lung cancer cases were reported by CDC-
anaged local cancer registries between January 1, 2003 and
ecember 31, 2010. Diagnoses were either pathologically orinically confirmed within 1 year of interview. Cases were required
be female, at least 18 years old, residents of the respective county
r at least 5 years, and in a stable medical condition as determined by
eir physicians. Premenopausal cases were excluded because their
trogen biosynthesis and metabolism are different from postmeno-
usal women [30,31]. Post-menopausal cases who had undergone
duced menopause (menopause due to surgery, radiotherapy, and
her reasons) were also excluded [29]. There were a total of 680 cases
igible for the present analysis.
Controls of the JFC Study were females randomly selected from
e same county as the cases. The JFC Study individually matched
ntrols to cases by age (+/− 5 years). In the present analysis, all
stmenopausal female controls from controls for four cancer sites
ere combined in order to increase statistical power. The same as
ses, controls are those with natural menopause only. A total of 1808
ntrols were eligible for the present analysis.
A standardized epidemiological questionnaire including demo-
aphic characteristics, social economic status and menstrual/
productive history, and other risk or protective factors were
ployed to collect data for both cases and controls by face-to-face
terview. The interviewers were trained and the questionnaire was
eld tested as detailed in a previous study [32]. The quality of
rticipants' answers was validated logically by repeated or related
estions. A variable was coded as missing if the participant had
consistent answers to the repeated/related questions.
xposure Ascertainment
The standard epidemiological questionnaire collected information
exposures of interest, which were hormonal factors including age
menarche and menopause, parity, gravidity, live birth, outcome of
rst pregnancy, induced abortion, and oral contraceptive (OC) use.
he outliers of ages at menarche and menopause, as well as
ntradictory answers in reference to current age, were treated as
issing data. The normal distributions of ages at menarche and
enopause were compared to large observational studies conducted
China among women with similar years of births in the JFC Study
3,34]. Three-sigma rule of thumb [35] was used to identify outliers
r these two variables. Reproductive window was calculated as the
fference between age at menopause and menarche. Gravidity and
rity are the numbers of times a female has been pregnant and
rried the pregnancies to a viable gestational age, respectively.
herefore, gravidity was calculated as the sum of numbers of
iscarriages, abortions, live births, stillbirths and all other outcomes
pregnancy. Parity was calculated as the total number of live births
d stillbirths [36]. Missing data in number of live births,
iscarriages, induced abortions and stillbirths were imputed with
e medians in the control group. The number of ovulatory cycles was
lculated based on the reproductive window, subtracted by the
ngth of time without ovulation due to OC use, live births,
illbirths, miscarriages, induced abortions, and breast feeding
7,38]. It was calculated assuming 36, 28, 12, and 12 weeks of no
ulatory cycles due to a live birth, a stillbirth, a miscarriage, and an
duced abortion, respectively. It was also assumed that there was no
ulation during OC use. If the participant's answer to the
eastfeeding question was ‘breast feeding only’, ‘no breast feeding’,
d ‘mixed feeding’, the length of time without ovulatory cycles after
livery was assumed to be 24, 6, and 9 months, respectively.
wenty-eight days was applied as the average length of an ovulatory
cle and 52.178 weeks in a year was assumed. In the study of
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Translational Oncology Vol. 12, No. 6, 2019 Smoking, Hormonal Factors, and Lung Cancer Jin et al. 821teraction with smoking status, selected menstrual and reproductive
ctors were dichotomized in order to calculate RERI (relative excess
sk due to interaction) and ROR (ratio of the odds ratios).
The questionnaire also collected information on demography and
variates: age at interview, county of residence, income, education,
oking status, pack-years of smoking, body mass index (BMI), and
mily history of lung cancer. Age at interview was calculated based on
lf-reported date of birth. If the participant only remembered the
nar month of birth, the following solar month was used as the
oxy. There were no missing data for year of birth. In cases of
issing month or date of birth, the median values (July and 15th,
spectively) were used as the estimations. BMI cut points were
osen for underweight (b18.5 kg/m2), normal weight (18.5 kg/m2
b24 kg/m2), overweight (24 kg/m2 to b28 kg/m2) and obesity
= 28 kg/m2) according to the standards for Chinese populations
9]. Ever smoking was defined as having smoked more than 100
garettes in one's lifetime. The missing values for pack-years of
oking (missing rate = 12.6%) were imputed with the county, sex,
d age-specific median values of the controls. Family history of lung
ncer was defined as lung cancer diagnosis in any family member
cluding parents, grandparents, siblings, children, spouses, and
rents' siblings. Income was measured as the per-capita annual
come of the household including wages, bonuses, and allowances
an average over the most recent decade.(S
in
Ta le 1. The Distribution of Demographic and Major Risk Factors in Cases and Controls
Lung Cancer Controls P
To l Number 680 (27.33) 1808 (72.67)
Mean(SD) Mean(SD)
Ag (continuous) 66.79 (9.36) 67.37 (9.32) .1641
N(column%) N(column%)
Ed cation .1783
literate 554 (81.71) 1431 (79.50)
imary School 106 (15.63) 294 (16.33)
iddle School + 18 (2.65) 75 (4.17)
In me .1783
1000 130 (19.88) 416 (23.44)
00–1499 131 (20.03) 382 (21.52)
00–2499 177 (27.06) 459 (25.86)
= 2500 216 (33.03) 518 (29.18)
Co nty b.0001
afeng 152 (22.35) 597 (33.02)
anyu 185 (27.21) 337 (18.64)
huzhou 120 (17.65) 365 (20.19)
ongshan 223 (32.79) 509 (28.15)
To acco smoking b.0001
ver 181 (26.62) 344 (19.03)
ever 499 (73.38) 1464 (80.97)
Pa -year b.0001
499 (73.38) 1464 (80.97)
10 25 (3.68) 68 (3.76)
0,20) 24 (3.53) 63 (3.48)
0,30) 51 (7.50) 91 (5.03)
0,40) 19 (2.79) 45 (2.49)
0,50) 25 (3.68) 33 (1.83)
0,60) 12 (1.76) 24 (1.33)
= 60 25 (3.68) 20 (1.11)
BM b.0001
8.5 115 (17.09) 155 (8.61)
.5 to b24 388 (57.65) 998 (55.41)
to b28 137 (20.36) 497 (27.60)
= 28 33 (4.90) 151 (8.38)
Fa ily history of lung cancer .0117
es 25 (3.68) 35 (1.94)
o 655 (96.32) 1773 (98.06)atistical Analysis
Cases and controls were compared using the χ2 test for categorical
riables and the Student t-test for continuous variables. The Mantel
end test was used to assess whether an association was exhibiting a
ear trend. The main effect was tested with multivariable
conditional logistic regression models, adjusting for covariates.
ccording to a priori biological rationale [5,27,40,41], age, county,
MI, exposure to tobacco smoking, pack-years of smoking, family
story of lung cancer, income, and education were adjusted for.
ratified analysis by smoking status was performed. In addition, age
menarche was adjusted for in the analysis for age at menopause and
e at first birth; length of reproductive window was adjusted for in
e analysis for parity/gravidity/number of children; age at first birth
as adjusted for in the analysis for outcome of first birth. Odds ratios
d 95% confidence intervals were calculated for all the possible
sociations. Semi-Bayes estimates and 95% posterior intervals were
lculated to mitigate the influence from sparse data and multiple
mparisons [42]. In the semi-Bayes estimation, the priors of
efficients in the logistic regressions were assigned normal distributions
ith mean of zero and variance of 0.5 (corresponding to OR = 1, 95%
= 0.25–4). And the priors were updated with observed values from
e study population. Therefore, the SB adjusted ORs have shrunk
wards the null. The effect modification by tobacco smoking was
lculated by RERI for the additive scale and was by ROR for the
ultiplicative scale. In these calculations, age, county, BMI, family
story of lung cancer, income, and education were adjusted for.
Complete case analyses were applied except where imputation was
scribed in “Exposure ascertainment”. The missing rates of those
riables with complete case analyses were all less than 10%. SAS
rsion 9.4 was used for statistical analysis. All p-values were based on
= 0.05 (two-sided). The JFC study was approved by the Human
bject Protection Committees of the Jiangsu Provincial Center for
isease Control (CDC) and the University of California at Losngeles (UCLA). Informed consent was obtained from all partici-
nts upon study enrollment.esults
mmary Statistics
The average age in this post-menopausal female population was
.21 years. Table 1 summarized the distribution of demographic and
ajor risk factors. Cases and controls showed similar average ages and
ucation/income distributions. Ganyu and Tongshan Counties
ntributed more lung cancer cases while Dafeng and Chuzhou
unties contributed more controls. Significantly higher proportions of
okers and larger pack-years were observed in lung cancer cases than in
ntrols. Cases were significantly more likely to be underweight and less
ely to be overweight or obese than controls. Family history of lung
ncer tended to happen among lung cancer cases rather than controls.
enstrual Characteristics
According to Table 2-1, there was no significant statistics for the
lationship between age at menarche and risk of lung cancer in the
tire study population. However, we found an 35% increased odds
able 2-2) among never smoking subpopulation, comparing age at
enarche between 16 and 17 years old with that b=15 years old
BOR: semi-Bayes adjusted odds ratio = 1.35, 95% PI, posterior
terval = 1.01–1.80). The Mantel test P-value was 0.03, indicating ab
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Table 2-1. Menstrual and Reproductive Factors in Association with the Risk of Lung Cancer in the Entire Study Population
All
Cases, n = 680 Ctrls, n = 1808 Adjusted OR1 SB-adjusted1 OR1
N % N % (95% CI) (95% PI)
Menstrual Characteristics
Age at menarche
b=15 224 33.33 639 35.56 1.00 (Ref) 1.00 (Ref)
16–17 262 38.99 689 38.34 1.20 (0.96, 1.51) 1.20 (0.96, 1.50)
N = 18 186 27.68 469 26.10 1.29 (1.00-, 1.68) 1.29 (1.00-, 1.66)
Ptrend
4 0.046 0.043
As a continuous variable8 1.05 (1.00-, 1.10) 1.05 (1.00-, 1.10)
Age at menopause5
b46 62 9.84 189 11.09 1.00 (Ref) 1.00 (Ref)
46–54 451 71.59 1307 76.66 1.02 (0.73, 1.43) 1.01 (0.73, 1.38)
N54 117 18.57 209 12.26 1.65 (1.10, 2.48) 1.61 (1.10, 2.36)
Ptrend 0.004 0.004
As a continuous variable8 1.03 (1.01, 1.06) 1.03 (1.01, 1.06)
Reproductive window
b=32 227 35.80 651 38.11 1.00 (Ref) 1.00 (Ref)
33–35 181 28.55 511 29.92 0.98 (0.76, 1.25) 0.98 (0.77, 1.24)
N = 36 226 35.65 546 31.97 1.10 (0.87, 1.40) 1.10 (0.87, 1.40)
Ptrend 0.441 0.406
As a continuous variable8 1.01 (0.99, 1.03) 1.01 (0.99, 1.03)
Reproductive History
Parity6
0 or 1 116 17.08 217 12.00 1.00 (Ref) 1.00 (Ref)
2–3 305 44.92 864 47.79 0.68 (0.51, 0.91) 0.70 (0.53, 0.93)
4 or more 258 38 727 40.21 0.72 (0.53, 0.97) 0.74 (0.55, 0.99)
Ptrend 0.177 0.18
As a continuous variable8 0.95 (0.89, 1.01) 0.95 (0.89, 1.01)
Gravidity6
0 or 1 104 15.32 195 10.79 1.00 (Ref) 1.00 (Ref)
2–3 275 40.50 773 42.75 0.69 (0.50, 0.93) 0.71 (0.53, 0.95)
4 or more 300 44.18 840 46.46 0.78 (0.58, 1.06) 0.80 (0.60, 1.08)
Ptrend 0.583 0.587
As continuous variable8
Number of live birth6
0 or 1 118 17.38 226 12.50 1.00 (Ref) 1.00 (Ref)
2–3 313 46.10 887 49.06 0.69 (0.52, 0.92) 0.71 (0.54, 0.94)
4 or more 248 36.52 695 38.44 0.73 (0.54, 0.99) 0.75 (0.56, 1.01)
Ptrend 0.227 0.227
As a continuous variable8 0.95 (0.89, 1.01) 0.95 (0.89, 1.01)
Life time abortion
Never 631 92.93 1650 91.26 1.00 (Ref) 1.00 (Ref)
Ever 48 7.07 158 8.74 1.03 (0.70, 1.51) 1.01 (0.70, 1.45)
As a continuous variable8 1.08 (0.84, 1.39) 1.05 (0.83, 1.34)
Outcome of first pregnancy7
Live birth 631 94.89 1656 94.04 1.00 (Ref) 1.00 (Ref)
Stillbirth 19 2.86 51 2.90 0.88 (0.48, 1.61) 0.91 (0.52, 1.58)
Miscarriage 14 2.11 46 2.61 1.02 (0.53, 1.97) 1.03 (0.57, 1.87)
Ectopic Preg 1 0.15 1 0.06 NA 0.91 (0.24, 3.49)
Induced abortion 0 0 6 0.34 NA NA
Number of Ovulatory Cycles
b=368 182 30.18 536 33.58 1.00 (Ref) 1.00 (Ref)
(368, 415] 192 31.84 537 33.65 0.96 (0.74, 1.24) 0.96 (0.75, 1.23)
N415 229 37.98 523 32.77 1.21 (0.94, 1.55) 1.21 (0.95, 1.55)
Ptrend 0.123 0.113
As a continuous variable (per 13 ovulatory cycles) 8 1.02 (1.00+, 1.04) 1.02 (1.00+, 1.04)
Exogenous Hormone
Oral Contraceptive use
Never 635 96.5 1649 94.66 1.00 (Ref) 1.00 (Ref)
Ever 23 3.50 93 5.34 0.93 (0.56, 1.55) 0.93 ((0.58, 1.50)
822 Smoking, Hormonal Factors, and Lung Cancer Jin et al. Translational Oncology Vol. 12, No. 6, 2019ssible dose–response relationship. Compared with ages at meno-
use between 46 and 54 years, those later than 54 years old were
sociated with 1.61 times of odds of lung cancer occurrence in the
hole study population (Table 2-1, SBOR = 1.61, 95% PI =
10–2.36, Mantel test P-value = 0.023). Age at menopause also
owed 3% increased odds of lung cancer per one-year increase
BOR = 1.03, 95% PI = 1.01–1.06). This aforementioned associ-
ion for age at menopause seemed to exist among never smokers butuld not be found in the ever-smoking subpopulation (Table 2-2).
here was no evidence demonstrating an association between the
ngth of reproductive window and the risk of lung cancer.
eproductive History
As reported in Table 2-1, a parity between two and three showed
% and a parity of four or more showed 26% decreased odds in lung
ncer occurrence, (parity = 2 or 3: SBOR = 0.70, 95% PI =
Table 2-2. Menstrual and Reproductive Factors in Association with the Risk of Lung Cancer, by Smoking Status
Never Smokers Ever Smokers
Cases,
n = 499
Ctrls,
n = 1464
Adjusted
OR2
SB-adjusted
OR2
Cases,
n = 181
Ctrls,
n = 344
Adjusted OR3 SB-adjusted OR3
N % N % (95% CI) (95% PI) N % N % (95% CI) (95% PI)
Menstrual Characteristics
Age at menarche
b=15 175 35.57 553 37.93 1.00(Ref) 1.00(Ref) 49 27.22 86 25.37 1.00(Ref) 1.00(Ref)
16–17 187 38.01 534 36.63 1.25 (0.96, 1.64) 1.26 (0.98, 1.63) 75 41.67 155 45.72 0.94 (0.57, 1.53) 0.94 (0.60, 1.48)
N = 18 130 26.42 371 25.45 1.34 (0.99, 1.82) 1.35 (1.01, 1.80) 56 31.11 98 28.91 1.01 (0.59, 1.74) 1.02 (0.62, 1.67)
Ptrend
4 0.050 0.03 0.962 0.953
As a continuous variable8 1.04 (0.98, 1.11) 1.05 (0.99, 1.11) 1.05 (0.94, 1.17) 1.05 (0.94, 1.17)
Age at menopause5
b46 48 10.39 147 10.71 1.00 (Ref) 1.00 (Ref) 14 8.33 42 12.65 1.00 (Ref) 1.00 (Ref)
46–54 319 69.05 1041 75.82 0.90 (0.61, 1.33) 0.91 (0.64, 1.30) 132 78.57 266 80.12 1.48 (0.72, 3.06) 1.23 (0.68, 2.21)
N54 95 20.56 185 13.47 1.45 (0.91, 2.29) 1.45 (0.95, 2.20) 22 13.1 24 7.23 2.48 (0.94, 6.51) 1.80 (0.85, 3.84)
Ptrend 0.035 0.023 0.066 0.077
As a continuous variable8 1.03 (1.00-, 1.06) 1.03 (1.00+, 1.06) 1.04 (0.98, 1.10) 1.04 (0.98, 1.10)
Reproductive window
b=32 151 32.54 503 36.53 1.00 (Ref) 1.00 (Ref) 76 44.71 148 44.71 1.00 (Ref) 1.00 (Ref)
33–35 134 28.88 409 29.70 1.00 (0.75, 1.35) 1.03 (0.78, 1.37) 47 27.65 102 30.82 0.79 (0.48, 1.30) 0.82 (0.51, 1.31)
N = 36 179 38.58 465 33.77 1.13 (0.86, 1.50) 1.16 (0.89, 1.51) 47 27.65 81 24.47 0.95 (0.57, 1.59) 0.97 (0.60, 1.57)
Ptrend 0.375 0.274 0.749 0.778
As a continuous variable8 1.01 (0.98, 1.04) 1.01 (0.99, 1.04) 1.01 (0.96, 1.06) 1.01 (0.96, 1.06)
Reproductive History
Parity6
0 or 1 80 16.06 176 12.02 1.00 (Ref) 1.00 (Ref) 36 19.89 41 11.92 1.00 (Ref) 1.00 (Ref)
2–3 242 48.59 753 51.43 0.69 (0.49, 0.97) 0.73 (0.53, 1.00+) 63 34.81 111 32.27 0.67 (0.35, 1.27) 0.76 (0.43, 1.35)
4 or more 176 35.34 535 36.54 0.74 (0.52, 1.08) 0.84 (0.60, 1.18) 82 45.30 192 55.81 0.52 (0.28, 0.97) 0.60 (0.35, 1.03)
Ptrend 0.332 0.62 0.114 0.116
As a continuous variable8 0.95 (0.88, 1.03) 0.97 (0.90, 1.04) 0.91 (0.81, 1.01) 0.91 (0.81, 1.01)
Gravidity6
0 or 1 71 14.26 159 10.86 1.00 (Ref) 1.00 (Ref) 33 18.23 36 10.47 1.00 (Ref) 1.00 (Ref)
2–3 222 44.58 677 46.24 0.73 (0.51, 1.05) 0.77 (0.55, 1.07) 53 29.28 96 27.91 0.57 (0.29, 1.12) 0.67 (0.37, 1.21)
4 or more 205 41.16 628 42.90 0.82 (0.57, 1.20) 0.92 (0.65, 1.30) 95 52.49 212 61.63 0.54 (0.29, 1.00+) 0.62 (0.36, 1.08)
Ptrend 0.684 0.902 0.268 0.263
As continuous variable8 0.98 (0.91, 1.05) 1.00 (0.93, 1.07) 0.89 (0.81, 0.99) 0.89 (0.81, 0.99)
Number of live birth6
0 or 1 82 16.47 183 12.50 1.00 (Ref) 1.00 (Ref) 36 19.89 43 12.5 1.00 (Ref) 1.00 (Ref)
2–3 249 50 770 52.60 0.69 (0.49, 0.98) 0.74 (0.54, 1.01) 64 35.36 117 34.01 0.67 (0.36, 1.27) 0.76 (0.43, 1.33)
4 or more 167 33.53 511 34.90 0.75 (0.52, 1.09) 0.84 (0.60, 1.18) 81 44.75 184 53.49 0.56 (0.31, 1.04) 0.64 (0.37, 1.09)
Ptrend 0.339 0.58 0.206 0.205
As a continuous variable8 0.94 (0.87, 1.02) 0.94 (0.87, 1.02) 0.92 (0.82, 1.03) 0.92 (0.82, 1.03)
Life time abortion
Never 463 92.97 1351 92.28 1.00 (Ref) 1.00 (Ref) 168 92.82 299 86.92 1.00 (Ref) 1.00 (Ref)
Ever 35 7.03 113 7.72 1.29 (0.81, 2.06) 1.23 (0.81, 1.87) 13 7.18 45 13.08 0.62 (0.31, 1.25) 0.66 (0.36, 1.22)
As a continuous variable8 0.66 (0.38, 1.16) 1.20 (0.92, 1.56) 0.66 (0.38, 1.16) 0.68 (0.41, 1.13)
Outcome of first pregnancy7
Live birth 460 94.65 1361 94.91 1.00 (Ref) 1.00 (Ref) 171 95.53 295 90.21 1.00 (Ref) 1.00 (Ref)
Stillbirth 15 3.09 36 2.51 1.05 (0.51, 2.15) 1.15 (0.62, 2.12) 4 2.23 15 4.59 0.43 (0.11, 1.61) 0.64 (0.26, 1.60)
Miscarriage 11 2.26 1 0.07 1.68 (0.76, 3.69) 1.59 (0.81, 3.11) 3 1.68 17 5.20 0.27 (0.07, 1.01) 0.49 (0.20, 1.19)
Ectopic Preg 0 0 29 2.02 NA NA 1 0.56 0 0 NA NA
Induced abortion 0 0 6 0.42 NA NA 0 0 0 0 NA NA
Number of Ovulatory Cycles
b=366 124 27.93 413 31.97 1.00 (Ref) 1.00 (Ref) 58 36.48 123 40.46 1.00 (Ref) 1.00 (Ref)
367–413 139 31.31 432 33.44 0.99 (0.73, 1.34) 0.97 (0.73, 1.30) 53 33.33 105 34.54 0.91 (0.55, 1.52) 0.92 (0.57, 1.47)
N = 414 181 40.77 447 34.60 1.18 (0.88, 1.59) 1.22 (0.92, 1.61) 48 30.19 76 25 1.16 (0.68, 2.00) 1.15 (0.70, 1.89)
Ptrend 0.233 0.135 0.63 0.632
As a continuous variable (per 13 ovulatory cycles) 8 1.02 (0.99, 1.04) 1.02 (1.00-, 1.04) 1.02 (0.98, 1.06) 1.02 (0.98, 1.07)
Exogenous Hormone
Oral Contraceptive use
Never 465 96.47 1327 95.06 1.00 (Ref) 1.00 (Ref) 170 96.59 312 93.13 1.00 (Ref) 1.00 (Ref)
Ever 17 3.53 69 4.94 1.16 (0.63, 2.14) 1.11 (0.64, 1.93) 6 3.41 23 6.87 0.58 (0.22, 1.54) 0.69 (0.32, 1.49)
Notation:
1. Odds ratios and 95% confidence intervals adjusted for age (as a continuous variable), smoking status (ever or never), pack-years of smoking, family history of lung cancer (yes or no), income, education, county of residence,
and BMI.
2. Odds ratios and 95% confidence intervals adjusted for age (as a continuous variable), family history of lung cancer (yes or no), income, education, county of residence, and BMI.
3. Odds ratios and 95% confidence intervals adjusted for age (as a continuous variable), pack-years of smoking, family history of lung cancer (yes or no), income, education, county of residence, and BMI.
4. Mantel trend test.
5. Additional adjustment for age at menarche (as a continuous variable).
6. Additional adjustment for length of reproductive window.
7. Additional adjustment for age at first birth.
8. Absolute number/count as the continuous variable.
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Table 3. Interaction with Smoking Status
Factor Case/Ctrl aOR (95%CI)1 Interactions (95%CI)1
Menarche at 17 or later Ever smoking
No No 275/838 1.00(Ref)
No Yes 94/170 2.36 (1.70, 3.27) RERI = −0.43 (−1.36, 0.5)
Yes No 217/620 1.28 (1.02, 1.61) ROR = 0.73 (0.47, 1.14)
Yes Yes 86/169 2.21 (1.56, 3.12)
Menopause at 55 or later Ever smoking
No No 367/1188
No Yes 146/308 1.98 (1.51, 2.59) RERI = 0.87 (−1.39, 3.12)
Yes No 95/185 1.60 (1.19, 2.15) ROR = 1.09 (0.53, 2.25)
Yes Yes 22/24 3.45 (1.80, 6.60)
Parity Ever smoking
ParityN = 3 No 335/1069
ParityN = 3 Yes 129/276 1.86 (1.40, 2.48) RERI = 0.96 (−0.39, 2.3)
Parity = 0, 1 or 2 No 163/395 1.32 (1.03, 1.69) ROR = 1.28 (0.76, 2.15)
Parity = 0, 1 or 2 Yes 52/68 3.13 (2.03, 4.83)
Gravidity Ever smoking
GravidityN = 3 No 352/1111
GravidityN = 3 Yes 132/290 1.77 (1.33, 2.34) RERI = 1.71 (0.03, 3.38)
Gravidity = 0, 1 or 2 No 146/353 1.26 (0.98, 1.62) ROR = 1.68 (0.98, 2.89)
Gravidity = 0, 1 or 2 Yes 49/54 3.73 (2.36, 5.90)
#live birth = 0, 1 or 2 Ever smoking
No No 333/1058
No Yes 128/273 1.85 (1.39, 2.47) RERI = 0.95 (−0.36, 2.27)
Yes No 165/406 1.30 (1.01, 1.66) ROR = 1.29 (0.77, 2.16)
Yes Yes 53/71 3.10 (2.02, 4.76)
Notation:
Point estimates and 95% confidence intervals were adjusted for age (as a continuous variable), family history of lung cancer (yes or no), income, education, county of residence, and BMI (categorical).
824 Smoking, Hormonal Factors, and Lung Cancer Jin et al. Translational Oncology Vol. 12, No. 6, 201953–0.93, parity = 4 or more: SBOR = 0.74, 95% PI =0.55–0.99,
ference group is parity = 1). The dose–response trend and change
r unit increase in parity were not statistically significant (Ptrend =
77 and the semi-Bayes posterior interval was across the null).
mong never smoking or ever smoking subpopulation (Table 2-2),
ere seemed to be no association between parity and the risk of lung
ncer. A moderate gravidity seemed to decrease risk of lung cancer by
% (SBOR = 0.71, 95% PI = 0.53–0.95, gravidity = 2–3 com-
red with gravidity = 0 or 1) in the study population (Table 2-1).
mong never smokers, gravidity did not show a significant
lationship with the risk of lung cancer. On the other hand, treated
a continuous variable, a one-unit increase in gravidity was
gnificantly associated with 11% decrease in risk of lung cancer
BOR = 0.89, 95% PI = 0.81–0.99) for ever-smokers. A moderate
mber of live births was shown associated with 29% decreased risk
lung cancer in all the post-menopausal women (SBOR = 0.71,
% PI = 0.43–0.94, number of live birth = 2–3 compared with
1). However, this statistical significance for number of live births
as not observed in either ever- or never- smokers (Table 2-2).
Induced abortion, reported or not in Tables 2-1 and 2-2, did not
ow any significant associations with lung cancer. A statistically
gnificant association between an increase of 13 ovulatory cycles (about
year) and 2% increase in the risk of lung cancer was shown in our post-
enopausal study population (SBOR = 1.02, 95% PI = (1.00+,
04)) but not observed in subpopulations stratified by smoking status.
xogenous Hormone Use
Tables 2-1 and 2-2 didn't show a relationship between OC use and
sk of lung cancer.
ffect Modification by and Interaction with Smoking Status
Tests for interaction with smoking status on additive and
ultiplicative scales were performed for menstrual and reproductivectors that showed statistically significant main effects. As reported in
able 3, gravidity at or below two showed an RERI of 1.71 with 95%
I of 0.33–3.38. The ROR of gravidity was 1.68 without statistical
gnificance. These RERIs and RORs were suggesting superadditivity
r the interaction between smoking and gravidity (Table 3).iscussion
the present analysis of hormonal factors, after controlling for
tential confounders and correction by semi-Bayes shrinkage, later
enopause was found to be associated with increased risk of lung
ncer. This relationship remained in the never-smoking subpopu-
tion, but disappeared in the ever-smoking subpopulation. A higher
rity, gravidity, and number of live births were respectively
sociated with reduced risk of lung cancer. Increased number of
ulatory cycles was associated with increased risk of lung cancer.
ther hormonal factors such as reproductive window, number of
ortions, and outcomes of first pregnancy were not associated with
ng cancer risk in our study population.
The stratified analyses for never- and ever-smokers indicated that
productive factors might interact with smoking status in the
velopment of lung cancer. Superadditivity was corroborated by
ERIs, showing a considerably greater joint effect of smoking and low
avidity than expected under an additive model without interactions.
Between 1/1/1988 and 7/31/2018, there were a total of 27
idemiologic studies [20–27] that tested for associations between
rmonal factors and risk of lung cancer. A meta-analysis [26] showed
statistically significant decreased risk of lung cancer with older age at
enarche among Caucasian-dominated North American female
pulations. The effect of hormonal factors on lung cancer varies by
ce/ethnicity and is inconsistent among Asian populations. In our
C Study, a menarche age greater than 18 years old could be a
arker of poor childhood nutritional status, which has long-term
verse influence on health [23,43,44]. This increased risk by later
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Translational Oncology Vol. 12, No. 6, 2019 Smoking, Hormonal Factors, and Lung Cancer Jin et al. 825enarche was also found in six other studies conducted among
hinese women [23,25,27,45–47] although there was one study with
tentially decreased risk linked to late menarche [22].
A greater menopausal age was proposed to increase the risk of lung
ncer since a greater menopausal age means more exposure to
trogen [18,19]. However, an ILCCO pooled analysis [20] with a
nsiderable number of missing values for exposure variables didn't
ow a significant result for this relationship. An Asian (Singapore,
CSP) cohort study [23] showed null associations without adjusting
r smoking intensity or pack-years of smoking, leaving potential
sidual confounding by smoking. In this present JFC Study, where
issing information was minimal and pack-years of smoking was
justed, significantly increased risk by greater age at menopause was
und. This finding was corroborated by two other studies among
hinese women [25,27].
In this present study, higher parity, gravidity, and live births were
sociated with decreased risk of lung cancer, which is consistent with
l other Asian studies [23,25,27]. Parity and gravidity take into
nsideration the effect by miscarriage, abortion, stillbirth, and live
rth. They cause an estrogen surge and accumulation for a period of
me and reduce the number of ovulatory cycles. Our study was the
st to report an increased risk associated with increased number of
ulatory cycles, supporting the hypothesis that regular dynamics of
trogen during normal ovulatory cycles, rather than accumulative
dogenous or exogenous estrogen exposure, might increase the risk
lung cancer.
It has long been believed that lung cancers not related to smoking
e different from those related to it [15,48]. This JFC study with
st-menopausal women is the first study to report the effect
odification by smoking, showing the risk smoking added to those
ith fewer pregnancies was greater than that added to those with
ore pregnancies.
Estrogen is thought to have an effect on lung cancer via estrogen
ceptors (ERs). Estrogen receptors α and β (ERα and ERβ), the two
ajor types of ERs, are found in bronchial and alveolar epithelia and
rway smooth muscle [14]. Both ERα and ERβ are ligand-activating
anscription factors activated by 17-β estradiol (E2), the activation
rm of estrogen in human. The binding of E2 to ERs leads to
merization and nuclear translocation of theses ERs. In the nucleus,
and-bound ERα/ERβ dimers bind to the estrogen response
ements (ERE) in the promoters of target genes to control cell
oliferation, differentiation and apoptosis. ERs also associate with
d activates EGFR (epidermal growth factor receptor, a receptor
rosine kinase) thus triggering MAPK/ERK (mitogen-activated
otein kinases/extracellular signal-regulated kinases) pathway and
/down regulating the transcription of genes that promote
oliferation and invasion of lung cancer cells [49].
Strengths of this current study included homogeneity in terms of
ce/ethnicity, a large sample size, and a large proportion of non-
okers, which are important to reduce bias. The weak effect of
enstrual and reproductive factors on lung cancer could be
detectable in a population dominated by smokers because of the
rong association between smoking and lung cancer [27]. This study
sign also minimized selection bias by having population-based
ntrols instead of hospital-based designs and by having very low
issing rates of exposure variables of interest. In previous studies of
e same topics, multiple menstrual and reproductive factors have
en tested at the same time within one analysis, possibly resulting in
lse positive findings from multiple comparisons without correction.our study, semi-Bayes shrinkage was applied to mitigate false
sitive by updating independent null priors for regression
efficients with observed data [50]. Semi-Bayes estimates were
lculated also to improve the sparse data problem [42].
The weaknesses of this study included a lack of histologic
tegorization of lung cancer cases. The suggested association between
rmonal factors and lung cancer has been identified most
ominently among adenocarcinoma with EGFR mutations
5,51]. In this present study, lung cancer cases were identified
om local CDC cancer registries. Due to the small proportion
0.4% cases) of lung cancer patients who had undergone surgeries or
doscope exams, there was not enough pathology or cytology
formation collected. Among these patients with known histology
formation, 65% of the NSCLC cases were adenocarcinoma. Among
her studies conducted in China, lung cancer histology was largely
minated by adenocarcinoma, accounting for 61% to 73% of all
male lung cancer diagnoses [22,51]. East Asian patients show a
uch higher prevalence of epidermal growth factor receptor (EGFR)
utations, compared with Caucasian patients with NSCLC
pproximately 30% vs. 7%, predominantly among patients with
enocarcinoma and never-smokers), thus showing a higher
oportion of patients who are responsive to EGFR tyrosine kinase
hibitors (EGFR-TKIs) [28,52].
Secondly, there could be recall biases brought by the case–control
udy design. However, all lung cancer cases were diagnosed within 1
ar of interview. In addition, the study was not initially designed to
st the association between hormonal factors and lung cancer and the
rticipants were never told so. Therefore, their recalls for their
posure information were relatively objective representations of their
ual life before the diagnosis of lung cancer and the recall bias has
en reduced to minimum. Lastly, the sample size in the interaction
udy was relatively small for some of the levels of the interacting
ctors. We were not able to verify the causal interaction between
oking status and those menstrual and reproductive factors.
onclusion
r postmenopausal Asian women, later menopause, more lifetime
ulatory cycles, and fewer pregnancies were associated with increased
k of lung cancer. This incremental risk appeared larger among ever
okers than their never-smoking counterparts. The potential etiological
ues of estrogen in the occurrence of lung cancer need to be further
plored by more epidemiologic studies with biomarkers measurements.
he identification of relationships between hormonal factors and the risk
lung cancer could inform preventive strategies and therapeutic regimes.
lthough causal interaction was not verified, the effect modification by
oking status could potentially add rationale to tobacco smoking
ssation interventions among certain female populations.
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